Department of Obstetrics and Gynaecology, Epsom & St Helier University Hospitals NHS Trust, London, UK.
Department of Obstetrics and Gynaecology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Eur J Obstet Gynecol Reprod Biol. 2022 Jan;268:100-109. doi: 10.1016/j.ejogrb.2021.08.028. Epub 2021 Aug 28.
Significant risk of bias and limitations in outcome selections in trials evaluating conservative treatments for the management of Pelvic Organ Prolapse (POP) have been highlighted and preclude comparability of outcomes, synthesis of primary studies and high quality evidence.
As systematic review of the reported outcomes is the first step in the process of development of a Core Outcome Set (COS), we aimed to systematically review reporting of outcomes and outcome measures in Randomised Control Trials (RCTs) on conservative treatments for POP and develop an inventory of them for consideration as core outcome and outcome measures sets. We evaluated methodological quality, outcome reporting quality and publication characteristics and their associations among published RCTs.
Systematic review of RCTs identified from the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE and MEDLINE (Pubmed). RCTs evaluating the effectiveness of conservative interventions for the management of POP were considered for inclusion. Outcomes and outcome measures were obtained from the RCTs and an inventory was created. Outcomes were grouped in domains and themes. Methodological quality, outcome reporting quality and publication characteristics were evaluated and statistically analysed.
Twenty-five trials (3179 women) were included and reported 31 outcomes and 50 outcome measures. Reporting rates of the outcomes investigated ranged between 4% and 56%. The most commonly reported outcome domains were patient reported symptoms, stage of POP expressed as POP-Q stage, and quality of life. Univariate analysis demonstrated no significant correlations of methodological and outcome reporting parameters.
There is a need to increase comparability of RCTs. Reporting standardized outcomes included in a COS for conservative interventions for POP will facilitate the comparability across RCTs. While the process of developing COS is in progress, we propose the interim use of the three most commonly reported outcomes in each domain: patient-reported outcomes (symptom distress including bowel and urinary symptoms, sexual function), stage of prolapse and quality of life parameters using validated questionnaires (Pelvic Floor Distress Inventory 20 (PFDI-20), Pelvic Floor Impact Questionnaire/Health related quality of life (PFIQ-7/HRQOL) and Pelvic Organ Prolapse Impact Questionnaire (POPIQ-7).
评估保守治疗盆腔器官脱垂(POP)管理的试验中,存在显著的偏倚风险和结局选择限制,这使得结局的可比性、主要研究的综合以及高质量证据受到影响。
由于系统评价报告结局是制定核心结局集(COS)过程的第一步,我们旨在系统评价保守治疗 POP 的随机对照试验(RCT)中报告结局和结局测量的情况,并建立一个清单,以供考虑作为核心结局和结局测量集。我们评估了已发表 RCT 的方法学质量、结局报告质量和发表特征及其相关性。
从以下数据库中系统检索 RCT:Cochrane 对照试验中心注册库(CENTRAL)、EMBASE 和 MEDLINE(Pubmed)。纳入评估保守干预治疗 POP 有效性的 RCT。从 RCT 中获取结局和结局测量值,并创建一个清单。将结局分为领域和主题。评估和统计分析方法学质量、结局报告质量和发表特征。
共纳入 25 项试验(3179 名女性),报告了 31 个结局和 50 个结局测量值。所研究结局的报告率在 4%至 56%之间。最常报告的结局领域是患者报告的症状、POP-Q 阶段表示的 POP 分期和生活质量。单变量分析显示,方法学和结局报告参数之间没有显著相关性。
需要提高 RCT 的可比性。报告包含在 POP 保守治疗 COS 中的标准化结局将促进 RCT 之间的可比性。在制定 COS 的过程中,我们建议在每个领域中使用三个最常报告的结局:患者报告的结局(包括肠道和泌尿系统症状、性功能的症状困扰)、脱垂分期和使用经过验证的问卷评估生活质量参数(盆腔器官脱垂/尿失禁性功能问卷 12 项(PISQ-12)、盆腔器官脱垂/尿失禁生活质量问卷 7 项(PFIQ-7/HRQOL)和盆腔器官脱垂影响问卷 7 项(POPIQ-7)。